Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Background:

• Resections to remove tumors in the liver, bile ducts and pancreas are rarely curative, and patients frequently succumb to disease recurrence in the ensuing months to year(s) after the operation.
• Standard adjuvant therapies, which typically begin 6-12 weeks after surgery, offer little demonstrable decreases in the rates of tumor recurrence.
• The concept and implementation of immediate perioperative therapy has not been evaluated given the serious concerns related to healing and recovery with standard cytotoxic chemotherapy and newer targeted agents.
• A significant percentage of metastatic colorectal cancers, and primary tumors of the pancreas and bile ducts express Sialyl Lewis, an epitope on the well-established tumor marker, Carbohydrate antigen 19-9 (CA19-9).
• MVT-5873, a fully human antibody against Sialyl Lewis, has displayed antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro, potentiated chemotherapeutic efficacy in mouse models and demonstrated efficacy in Phase 1 trials of patients with advanced inoperable Hepato-pancreato-biliary (HPB) cancers.
• MVT-5873 is well tolerated as a single agent; moderate elevations in aspartate aminotransferase (AST)/alanine aminotransferase (ALT) appear to be dose-limiting.
• Patients with resectable Sialyl Lewis-expressing cancers represent an ideal population to explore the use of perioperative MVT-5873 given moderate level of CA 19-9 elevations, and the potential for extension of recurrence-free survival.

Objectives:

• Document the safety of perioperative MVT-5873 in patients undergoing pancreas and liver resections.
• Determine if perioperative MVT-5873 can decrease 1-year recurrence rates for patients with operable CA 19-9-producing cancers.

Eligibility:

• Histologically or cytologically confirmed adenocarcinoma of the

• Colon (metastatic to liver)
• Pancreas
• Bile Ducts (Cholangiocarcinoma)
• Serum CA19-9 levels greater than the upper limit of normal, but less than 2500.
• Disease amenable to complete surgical extirpation.

Design:

-Pre-operative one-time treatment with MVT-5873, resection to remove all demonstrable disease in the liver, bile ducts and pancreas, and continuing MVT-5873 mono-therapy until off treatment criteria are met.

• INCLUSION CRITERIA:
• Subjects must have histologically or cytologically confirmed diagnoses of adenocarcinoma in one of the following scenarios:

• Primary tumors of the pancreas
• Primary tumors of the bile duct and ampulla
• Metastatic colorectal cancers to the liver
• Subjects must have disease resectable with a standard pancreatectomy (pancreaticoduodenectomy or distal pancreatectomy) or liver resection.
• Subjects may have received prior therapy, including neoadjuvant regimens.
• Subjects must have serum Carbohydrate antigen 19-9 (CA 19-9) elevations greater than the upper limit of normal but less than 2500 U/mL.
• Age greater than or equal to 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1
• Subjects must have adequate organ and marrow function as defined below:

• leukocytes >3,000/mcL
• absolute neutrophil count >1,500/mcL
• platelets >90,000/mcL
• For subjects with Periampullary cancers that require a pancreaticoduodenectomy for complete tumor extirpation:

• total bilirubin <10 upper limit of normal (ULN)*
• Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamate-pyruvate transaminase (SGPT) <5 X institutional upper limit of normal
• creatinine <1.5X institutional upper limit of normal

• Subjects with periampullary cancers typically present with biliary obstruction resulting in significant abnormalities in liver function tests that do not reflect liver dysfunction. These values normalize after tumor removal. They can be normalized pre-operatively with biliary stenting, but several large studies have demonstrated an increase in infectious complications with drainage. As such, a practice standard has been to avoid stenting until bilirubin level rises above 10 X ULN.
• For subjects with liver tumors (cholangiocarcinoma or metastatic colorectal cancer) requiring a hepatectomy for complete tumor extirpation:

• total bilirubin <2.5 X institutional upper limit of normal*
• AST(SGOT)/ALT(SGPT) <5 X institutional upper limit of normal*
• creatinine <1.5X institutional upper limit of normal

• Liver abnormalities in this range are consistent with parenchymal destruction from the tumor.
• For subjects with pancreas tumors that require a distal pancreatectomy for extirpation:

• total bilirubin <1.5 X institutional upper limit of normal*
• AST(SGOT)/ALT(SGPT) <2 X institutional upper limit of normal*
• creatinine <1.5X institutional upper limit of normal

• Liver abnormalities in this range are consistent with pancreas cancer destruction from the tumor.
• The effects of MVT-5873 (HuMab-5B1) on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 3 months after completion of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Ability of subject to understand and the willingness to sign a written informed consent document.
• Subjects must agree to co-enrollment on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors.

Exclusion criteria

• Presence of disease outside the confines of a standard operation for subjects with periampullary cancers (pancreatic and cholangiocarcinoma).
• Presence of disease outside the liver for subjects with intrahepatic/hilar cholangiocarcinoma or metastatic colorectal cancer, other than a primary tumor for subjects with metastatic colorectal cancer.
• Subjects who are receiving any other investigational agents.
• Fewer than 28 days (or 5 half-lives for systemic agents, whichever is shorter) from the last day of prior anticancer therapy, including chemotherapy, hormonal, investigational, and or biological therapies and irradiation.
• Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study

requirements.

-Active concurrent malignancies within the last five years other than the primary tumor

in subjects with metastatic colorectal cancer, basal or squamous cell skin carcinoma or non- medullary thyroid carcinoma.

• Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects of the MVT-5873. Because there is an unknown but potential
• Subjects with active, Hepatitis B or C infection because of the potential for increased liver toxicity given the damaging effects of the virus.
• Allergic to chimeric, humanized or human antibodies.
• Received live vaccine within 4 weeks prior to first date of study intervention.
• Infection requiring hospitalization or herpes zoster treatment within 2 weeks prior to the first date of study intervention.
• Long-term infectious diseases (tuberculosis, fungal infections) active within 2 years prior to the first date of study intervention.